Biotech group Biophytis to recruit more patients for COVID-19 treatment trial
17/02/2021 07:15
PARIS, Feb 17 (Reuters) - Biotechnology group Biophytis
ALBPS.PA said it had received regulatory approval in France
and Belgium to recruit more patients for a study of Sarconeos as
a potential treatment for breathing problems associated with
COVID-19.
"We are extremely pleased that Part 2 of the COVA Study has
now also been authorised in France and Belgium," Biophytis CEO
Stanislas Veillet said in a statement on Wednesday.
(Reporting by Sudip Kar-Gupta; editing by Jason Neely)
((sudip.kargupta@thomsonreuters.com; +33 1 49 49 53 84;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon